key: cord-1039185-bd3j4m8c authors: Rosen, Hugo R.; O'Connell, Casey; Nadim, Mitra K.; DeClerck, Brittney; Sheibani, Sarah; DePasquale, Eugene; Sanossian, Nerses; Blodget, Emily; Angell, Trevor title: Extrapulmonary Manifestations of Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Infection date: 2020-10-14 journal: J Med Virol DOI: 10.1002/jmv.26595 sha: 1225f6427d5da78f246d903985201864214573b7 doc_id: 1039185 cord_uid: bd3j4m8c COVID‐19, the infectious disease caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), has resulted in a global pandemic with unprecedented health, societal and economic impact. The disease often manifests with flu‐like symptoms and is dominated by pulmonary complications, but widely diverse clinical manifestations involving multiple organ systems can result. We posit that viral tropism and the aberrant host immune response mediate the protean findings and severity in this disease. In general, extrapulmonary manifestations are a harbinger of or contemporaneously associate with disease progression, but in the case of some extrapulmonary findings (GI and dermatologic), may track with milder disease. The precise underlying pathophysiological mechanisms remain incompletely elucidated, and additional immune phenotyping studies are warranted to reveal early correlates of disease outcomes and novel therapeutic targets. This article is protected by copyright. All rights reserved. IL-17, G-CSF, GM-CSF, IP10, MCP1, MIP1α, TNFα and inflammatory chemokines (CCL2, CCL3, CXCL10) in patients with severe COVID-19, which can lead to septic shock and multi-organ failure 6, 7 . Macrophages show the highest number of interactions and potential crosstalk with ACE2-expressing cells in multiple organs 3 , and inflammation may upregulate ACE2 expression on macrophages 5 , further amplifying viral sensing and tissue injury. Postmortem analyses of secondary lymph nodes and spleen implicate CD169 + macrophages that contain viral nucleocapsid protein as mediators of activation-induced cell death (AICD) of lymphocytes 8 . T cell exhaustion with higher expression of PD-1 and Tim-3 has been demonstrated in patients with advanced COVID-19 disease 6 . As reviewed here, the dysregulation of innate immune and hemostatic mechanisms, two critical emergency response pathways that maintain homeostasis under controlled circumstances 9 , have mechanistic underpinnings for the development of COVID-19-related complications. The decreased effector function and frequency of cells involved in pathogen clearance coupled with prolonged hospitalization of many patients with COVID-19 potentially impacts the risk of coinfection with other viruses, bacteria, and fungus. Procalcitonin, advocated as a marker for severe bacterial infections 10 , is not elevated in patients with non-complicated COVID-19 at admission but its progressive increase is associated with nearly 5-fold higher risk of evolution towards a more severe course of disease 11 . Although it is known that This article is protected by copyright. All rights reserved. rates of secondary infection are significantly increased in patients with severe COVID-19, e.g., half of non-survivors experienced a secondary infection in a series from Wuhan, China 12 , the overall rate of bacterial or fungal co-infection in total COVID-19 cases is estimated to be 8%. 13 Despite this, more than 70% of patients with COVID-19 received empiric antimicrobial therapy, frequently broadspectrum and in non-critical care settings 13 . Remarkably, in one report from Wuhan, among patients in the intensive care unit (ICU) who died, > 55% of COVID-19 patients were coinfected with carbapenem-resistant Acinetobacter baumanni, although the 17% rate of infection in the recovering COVID-19 ICU toward transfer patient group is also very high 14 In a series from New York City 15 , bacteremia was noted in almost 12% of patients on invasive mechanical ventilation versus less than 2% in those not ventilated. These studies likely underestimate the actual rate of coinfection in this population since the diagnosis of hospital-or ventilator-associated pneumonias may depend on invasive procedures such as endotracheal aspirate or bronchoalveolar lavage, which may not be performed due to risk of exposure of healthcare providers.. Approximately 21% of patients with SARS-CoV-2 will test positive for another respiratory pathogen, including rhinovirus/enterovirus and respiratory syncytial virus, which is comparable to the rate observed in symptomatic patients)cough, fever, dyspnea) who are negative for SARS-CoV-2 16 . Numerous hematologic findings and complications of SARS-CoV-2 infection have been identified. Lymphopenia, which may result from tissue This article is protected by copyright. All rights reserved. Accepted Article recruitment or lymphocyte apoptosis (more pronounced for CD8 + T cells) 5 following viral-receptor binding or indirectly through cytokine activation, is a cardinal laboratory finding that occurs in >80% of patients, and lower lymphocyte count is associated with the risk of ARDS 17 18 . Coagulation disorders are also frequently encountered, particularly among those with severe disease 12 19 . In a multicenter retrospective study of 560 patients during the first two months of the pandemic in China, 260 (46.4%) had elevated D-dimers (>0.5 mg/L) 20 . Elevated D-dimers (fibrin degradation products) correlate with mortality, and non-survivors had a significant rise in serial values over the course of their hospitalization while survivors' D-dimers remained relatively low 12 . In one series 21 , more than 70% of patients who died of COVID-19 complications fulfilled the clinical criteria (elevated D-dimer, fibrinogen, prolonged PT, and thrombocytopenia) 22 for disseminated intravascular coagulation (DIC), with a median time from admission to DIC manifestation of 4 days. As COVID-19 spread to Europe and the United States, mounting data indicated another concerning clinical problem: increased venous thromboembolism (VTE) rates in patients with COVID requiring ICU care despite appropriate pharmacologic prophylaxis. In the first cohort of ICU patients with COVID-19 reported from the Netherlands (n=184), where low molecular heparin prophylaxis was given to all patients, the cumulative incidence of VTE was 27%, and an additional 4% of patients developed an arterial event 23 . In a follow-up to that report, the cumulative incidence at 14 days of the combined endpoint increased to 49%, with 65 (35%) patients diagnosed with pulmonary embolism (PE) 24 , the majority involving segmental or more proximal arteries. This article is protected by copyright. All rights reserved. Importantly, diagnostic testing for VTE was only performed in patients with suggestive symptomatology, so the actual rate of deep venous thrombosis (DVT) may have been underestimated. Another Dutch study evaluated the cumulative incidence of symptomatic and asymptomatic patients in the ICU and the general wards 25 with the majority of patients receiving standard pharmacologic prophylaxis. Among patients in the ICU, 47% developed VTE (28% symptomatic) with a cumulative incidence of 59% (34% symptomatic) at 21 days. Of note, none of the 19 patients who presented and remained on full dose anticoagulation developed VTE; only 3% of patients on the regular wards developed VTE with a cumulative incidence of 9.2% at 21 days. Moreover, microthrombi have been identified in the brain, heart, liver and kidneys of patients with COVID-19 5 . The pathophysiologic basis likely includes cytokine-, PAMP-and DAMP-mediated activation of endothelium, platelets, monocytes and possibly complement 9 5 . Activated endothelial cells recruit neutrophils which can form neutrophil extracellular traps (NETs), scaffolds comprised of nuclear DNA studded with histones and granule proteins representing in many cases a process of cell death 26 , that induce the coagulation contact pathway and amplify plateletmediated clotting 5 . Tissue factor (CD142 or coagulation factor III pathway) is expressed on monocytes in response to pro-inflammatory cytokines as well as on endothelial cells, promoting the transformation of prothrombin into thrombin, converting circulating fibrinogen into fibrin and resulting in tissue damage and microangiopathic pathology 5 9 (Figure 1 This article is protected by copyright. All rights reserved. Cardiac complications are common in SARS-CoV-2 infection (~20-25%) 12 27 , and the prevalence and risk of death of severe COVID-19 is higher in older patients with chronic comorbidities (e.g., arterial hypertension, diabetes, cardiac and cerebrovascular disorders) 28 . Patients presenting with evidence of cardiac injury are more prone to have coagulation disorders (7.3%) as compared to those without cardiac signs (1.8%) 29 . Between 7 and 28% of SARS-CoV-2 infected patients have elevated troponin levels 30 19 27 29 that may be the result of direct myocarditis through viral infection, cytokine storm, and coronary microvascular ischemia (endothelium with viral inclusion bodies, inflammation and resultant dysfunction, including vasoconstriction 30, 31 ). Troponin levels have prognostic implications: those with elevated levels at baseline have a greater risk of severe disease, increased intensive care unit admissions and significantly higher mortality 27 29 . In a cohort study, the presence of elevated troponin levels was associated with mortality (hazard ratio 4.26; 95% CI 1.92-9.49). In a single-center retrospective study of 187 COVID-19 patients, the risk of death increased linearly stratified by the presence of elevated troponin-T and/or presence of prior cardiovascular disease [7.62% (no cardiovascular disease history); 13% (cardiovascular disease history); 37.5% (elevated troponin only); 69% (elevated troponin and cardiovascular disease history)] 27 . Therefore, troponin elevation may even carry prognostic significance in the absence of cardiovascular disease; non-survivors showed a trend of progressive increase in troponin levels, suggesting that elevation may reflect progression of COVID-19 disease to a severe stage 32 . Cardiac arrhythmias are also frequent, occurring in ~17% of patients 19 . 33 . Echocardiographic assessment in 100 consecutively admitted COVID-19 also revealed a high prevalence of abnormalities (68%) with right ventricular dilatation and dysfunction (39%) being the most common, followed in frequency by left ventricular diastolic (16%) and systolic (10%) dysfunction 34 . Patients with COVID-19 can present with gastrointestinal (GI) symptoms which may precede respiratory manifestations of disease by 1-2 days 19 . A recent meta-analysis reported the overall pooled prevalence for abdominal pain (3.6%), diarrhea (7.7%), and nausea or vomiting (7.8%) 35 . GI symptoms, without any respiratory involvement is rare, and seen in only about 3% of patients 36, 37 . Patients with GI symptoms are more likely to have a longer disease duration ( ≥1 week) compared to those without (33% vs 22%), although they may be less likely to require ICU admission 38 . In particular, diarrhea has been associated with slightly longer interval between the symptom onset and hospital admission, possibly reflecting a delayed recognition of GI symptoms as being COVID-19 related. 36 Diarrhea lasts an average duration of 5.4 days (with a frequency of 4.3 ± 2.2 bowel movements per day) and is usually self-limited 39 . Patients with GI symptoms are more likely to have a positive viral RNA stool tests compared to those without GI symptoms (73% vs 14%, p=0.033) 39 . Nevertheless, there are conflicting data whether detection of viral RNA confers infectivity, as this may be This article is protected by copyright. All rights reserved. indicative of live virus or inactivated viral particles. 40 41 However, considering that more than 20% of patients with SARS-COV-2 demonstrate positive viral RNA in feces after respiratory track tests have converted to negative, fecal-oral transmission could be an additional route for viral spread 42 , warranting enhanced control measures to prevent spread 43 . Liver biochemistry test abnormalities are also frequently noted in patients with COVID-19: elevated aspartate aminotransferase or alanine aminotransferase in 15% and hyperbilirubinemia in ~17%. 35 Patients with abnormal liver enzymes were more likely to have higher inflammatory indices such as C-reactive protein and procalcitonin and fevers, and a higher proportion were receiving treatment with lopinavir/ritonavir compared to those with normal LFTs. 44 Abnormal liver tests at presentation is prognostically significant, associated with a greater than 2-fold risk of developing severe disease or requiring ICU admission. 45 46 Endocrinologic manifestations are frequent in patients presenting with SARS-CoV-2 infection. The prevalence of diabetes mellitus (DM) amongst COVID-19 studies varies substantially (~5%-44%) and may reflect estimated prevalence in the respective population 47 48 48 . Hyperglycemia and DM are positively associated with COVID-19 disease severity and risk of death. In 1099 patients from China, 26.9% of patients with DM had ICU admission, mechanical ventilation, or death compared to 6.1% of non-DM patients 20 . Early data from the United States (US) showed that 24%-35% of hospitalized patients had DM 49 50 . Meta-analyses have found DM to be consistently associated with risk of severe Accepted Article disease or mortality (OR 1.90-3.21) 6, 7 20 and a large whole-population study confirmed DM as a risk factor for in-hospital COVID-19-related death after adjustment for demographics and comorbidities 51 . Acute hyperglycemia itself is a manifestation of COVID-19 with negative prognostic significance 52 53 . Hyperglycemia without preexisting DM occurred in 14.3% of hospitalized patients in a US series, and in-hospital mortality was 41.7% in this group 52 . Ketoacidosis also may complicate COVID-19 in patients with DM, noted in more than 10% of hospitalized cases 54 . The underlying mechanisms include the low-grade inflammation that characterizes obesity that is further exacerbated by the cytokine storm induced by SARS-CoV-2 infection. Moreover, there is expression of ACE2 in pancreatic islets 55 56 , which is enhanced in patients with DM/hyperglycemia compared to controls without DM 56 , raising the possibility that direct damage to pancreatic islets through SARS-CoV-2 -ACE2 binding may contribute to hyperglycemia. Thyroid dysfunction may accompany SARS-CoV2 infection, either as biochemical thyrotoxicosis (20-56%) and hypothyroidism (5%) 57 58 . Lower TSH and triiodothyronine (T3) levels are associated with severity of illness and mortality from COVID-19 7 57 58 . However, pre-existing hypothyroidism was not associated with an increased risk of hospitalization, mechanical ventilation, or death 59 , suggesting risk may not be due to underlying thyroid disease per se. with classic neck pain and thyrotoxicosis, fever, cardiovascular manifestations and elevated inflammatory markers several weeks after resolution SARS-CoV-2 This article is protected by copyright. All rights reserved. infection 60 61 . Because the initial symptoms of COVID-19 may have been mild in patients presenting with SAT, assessment for preceding SARS-CoV-2 exposure may be warranted in such patients. Acute kidney injury (AKI) in patients with COVID-19 is a frequent complication that may be caused by direct infection of the kidney by SARS-COV-2 with tubular injury, pigment casts due to rhabdomyolysis, endothelial damage, glomerular thrombi 62,63 , cytokine storm and/or hemodynamic changes due to severe sepsis and multiorgan failure 7 . In the largest series published in the US (n=5,449), the incidence of AKI was 36.6% of which 14.3% required renal replacement therapy (RRT) with a mortality rate of 35% in those who developed AKI. 64 Older age, black race, diabetes mellitus, cardiovascular disease, hypertension and need for ventilation and vasopressor medications were associated with higher risk for developing AKI and associated with higher mortality. AKI has been reported to occur from 24 hours to 15 days after admission. 12, 64, 65 Additionally, a high frequency of other renal abnormalities have been demonstrated in a few studies, with 40-65% presenting with proteinuria, 27-46% with hematuria and 44% with both. [64] [65] [66] Presence of AKI, proteinuria or hematuria, have been independently associated with a higher risk of mortality. 7, 12, 65, 66 Currently the only treatment for COVID-19 with AKI is supportive management and RRT, with delivery of the latter potentially being compromised by the higher risk of thrombosis of central lines and dialysis access related to SARS-CoV-2 infection-related hypercoagulability. Prior to seeking medical care, This article is protected by copyright. All rights reserved. patients may be experiencing fever and GI symptoms including nausea, vomiting and diarrhea making them prone to intravascular volume depletion and pre-renal AKI. In these patients, early aggressive volume resuscitation with balanced solutions may prevent the development of acute tubular injury due to prolonged severe renal hypoperfusion. However, caution should be taken when administering fluids as too little may promote hyper-coagulation and worsen AKI, while a positive fluid balance may worsen gas exchange and is an independent predictor of worse outcomes in critically ill patients. Similar to all AKI, the best timing of RRT remains controversial. [67] [68] [69] [70] In the absence of an urgent indication, a delayed approach to RRT initiation may be considered during the COVID pandemic when RRT resources are stretched thin 71 , should be individualized and considered in patients in whom metabolic and fluid demand surpasses the capacity of the kidney. 72 The cutaneous manifestations of SARS-CoV-2 infection occur frequently (>20%), are quite varied and can be grouped into five main distinctive morphologic categories: morbilliform (maculopapular), urticarial, vesicular, pernio/chilblains-like, and necrotic/livedoid 73 . Other less common cutaneous findings include: a papulosquamous, pityriasis rosea-like eruption, a perifollicular papular eruption, erythema multiforme-like lesions, axillary erythema or purpura, a Dengue fever-like petechial eruption, an enanthem, and edematous papules of the dorsal hands or other extensor surfaces. The majority of dermatologic findings occur either concurrently (56%) or after (37%) other manifestations of This article is protected by copyright. All rights reserved. COVID-19 73 . Morbilliform eruptions are the most common reported cutaneous finding in COVID-19 patients, representing 47% of all cutaneous eruptions in the Spanish cohort 73 and 16% of all patients in the Italian study 74 . The morphology was not uniform with some patients showing the additional findings of purpura, petechiae, pityriasis rosea-like scale, or edema leading to a pseudovesicular pattern (mainly on the dorsal hands) (Figure 1) . These patterns can be common to other viral exanthems and are not considered specific for COVID-19. Pernio/Chilblains-like eruptions are characterized by acral erythema and sometimes vesicles, pustules, or purpura on the hands and feet; the toes are the most frequently involved sites (Figures 1) . This pattern occurred in 19% of the Spanish COVID-19 cases with cutaneous findings 73 . Of note, this pattern is described mostly in the young, portends a good prognosis, and may show a delayed onset. Pain or pruritus may be present, but patients may lack other characteristic signs and symptoms of COVID-19. If more typical COVID-19 symptoms are present, they are typically mild. Furthermore, patients may test negative for COVID-19 at the time of this eruption; it has been suggested that a robust Type I interferon response (which is deficient in patients who develop severe COVID-19 disease 75 ) may limit viral replication but induce this late autoinflammatory manifestation 76 . In contrast, livedoid/necrotic lesions, seen in 6% of the Spanish cohort 73 , particularly in elderly individuals, were associated with coagulopathies and a 10% mortality. This article is protected by copyright. All rights reserved. Neurological manifestations of SARS-CoV-2 infection are common, being reported in about 36% of hospitalized patients 77 81 In addition, about one-third of patients have ocular findings (e.g., conjunctival hyperemia, chemosis, This article is protected by copyright. All rights reserved. Accepted Article epiphora, or increased secretions) particularly in patients with more severe disease 82 . In summary, it is important for the clinician to consider and identify the broad range of manifestations related to SARS-CoV-2 infection which can precede or be neglected due to respiratory impairment. Early consideration is paramount to avoid delayed diagnosis/ misdiagnosis or missing the opportunity to treat and prevent further transmission. In general, extrapulmonary manifestations are a harbinger of or contemporaneously associate with disease progression, but in the case of some GI and dermatologic findings, may track with milder disease. The precise underlying pathophysiological mechanisms remain incompletely elucidated, and additional immune phenotyping studies are warranted to reveal early correlates of disease outcomes and novel therapeutic targets. The first step in infection requires virus binding and entry to a host cell through angiotensin-converting enzyme 2 (ACE2)/transmembrane serine protease (TMPRSS2), expressed widely throughout the body 1,2,3 . The median incubation period is approximately 4-5 days before symptom onset, with fever and dry cough as the typical presenting symptoms; other symptoms include difficulty breathing, muscle and/or joint pain, headache/dizziness, and diarrhea 1 . Within 6 days of symptom onset, SARS-CoV-2 viral load reaches its peak. In the majority of patients, a healthy immune response (Inset A) neutralizing antibodies bind and inactivate SARS-CoV-2 and alveolar macrophages phagocytose neutralized viral particles and apoptotic cells, followed by generation of viral-specific T cell responses, eliminating infected cells and preventing cell-to-cell viral spread with minimal inflammation and lung damage. However, when the cytopathic effect of SARS-CoV-2 overwhelms the first line of innate immune response (Inset B), a form of programmed cell death known as pyroptosis leads to release of DAMPs and PAMPs that are recognized both locally and distally in the body. Inflammation characterized by chemo-attraction to lung tissue and activation of immune cells leads to a "cytokine storm" that is reflected by high circulating levels (IL-6, IFN-γ, MCP1, MIP1α, and IP-10) and can result in septic physiology. Further, non-neutralizing antibodies produced by B cells may worsen organ damage through antibody-dependent enhancement (ADE) and increase hyperinflammatory responses 1, 6 (adapted from 1 ). In addition to the wellcharacterized pulmonary manifestations, SARS-CoV-2 induces protean clinical findings that include neurologic, ocular, cardiac, gastrointestinal/hepatic, renal, dermatologic (Pernio/Chilblains-like acral eruption on hand and foot are shown), and hematologic abnormalities. The increased risk of thrombotic phenomenon, including microthrombi within many organs, is possibly related to direct viral infection of endothelium 30 and indirect inflammatory-mediated mechanisms, including neutrophil extracellular traps (NETs) which have the potential to initiate and propagate inflammation and thrombosis (Inset C) 5 83 . Circulating cytokines, DAMPs, and PAMPs trigger activation of blood monocytes to induce tissue factor (TF) membrane expression. Endothelial cells take up viral particles and produce chemo-attractants that recruit monocytes and upregulate adhesion molecules. Tissue factor activates the extrinsic coagulation pathway that leads to fibrin deposition and blood clotting. Neutrophils are recruited by activated endothelial cells and can release neutrophil extracellular traps (NETs), scaffolds comprised of nuclear DNA studded with histones and granule proteins representing in many cases a process of cell death 26 , that induce the coagulation contact pathway and amplify platelet-mediated clotting (adapted from 5 ). The trinity of COVID-19: immunity, inflammation and intervention SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses Antibody responses to SARS-CoV-2 in patients with COVID-19 Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages COVID-19: immunopathology and its implications for therapy Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan Clinical Characteristics of Covid-19 in New York City Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens Hematological findings and complications of COVID-19 Clinical observation and management of COVID-19 patients Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical Characteristics of Coronavirus Disease 2019 in China Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis Incidence of venous thromboembolism in hospitalized patients with COVID-19 Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Endothelial cell infection and endotheliitis in COVID-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Electrocardiographic Findings in COVID-19: Insights on Mortality and Underlying Myocardial Processes The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19) -a Systematic Echocardiographic Study AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19 Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes Detection of SARS-CoV-2 in Different Types of Clinical Specimens Virological assessment of hospitalized patients with COVID-2019 Evidence for Gastrointestinal Infection of SARS-CoV-2 Faecal-oral transmission of SARS-COV-2: practical implications Clinical Features of COVID-19-Related Liver Functional Abnormality Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications COVID-19: Abnormal liver function tests Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2 Acute Kidney Injury in Patients Hospitalized with COVID-19 Kidney disease is associated with inhospital death of patients with COVID-19 Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients Patient Selection and Timing of Continuous Renal Replacement Therapy Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases Cutaneous manifestations in COVID-19: a first perspective Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 A case report with histopathologic findings. JAAD Case Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19 Neutrophil extracellular traps and thrombosis in COVID-19. medRxiv The trinity of COVID-19: immunity, inflammation and intervention SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses Antibody responses to SARS-CoV-2 in patients with COVID-19 Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages COVID-19: immunopathology and its implications for therapy Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Epidemiology, Pathogenesis, and Control of COVID-19 Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan Clinical Characteristics of Covid-19 in New York City Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens Hematological findings and complications of COVID-19 Clinical observation and management of COVID-19 patients Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan Clinical Characteristics of Coronavirus Disease 2019 in China Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis Incidence of venous thromboembolism in hospitalized patients with COVID-19 Neutrophil extracellular traps: double-edged swords of innate immunity Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Endothelial cell infection and endotheliitis in COVID-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Electrocardiographic Findings in COVID-19: Insights on Mortality and Underlying Myocardial Processes The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19) -a Systematic Echocardiographic Study AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19 Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes Detection of SARS-CoV-2 in Different Types of Clinical Specimens Virological assessment of hospitalized patients with COVID-2019 Evidence for Gastrointestinal Infection of SARS-CoV-2 Faecal-oral transmission of SARS-COV-2: practical implications Clinical Features of COVID-19-Related Liver Functional Abnormality Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications COVID-19: Abnormal liver function tests COVID-19 in people with diabetes: understanding the reasons for worse outcomes Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care COVID-19 infection may cause ketosis and ketoacidosis ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection Expression Profile of SARS-CoV-2 Host Receptors in Human Pancreatic Islets Revealed Upregulation of ACE2 in Diabetic Donors Thyrotoxicosis in patients with COVID-19: the THYRCOV study Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series Subacute Thyroiditis After Sars-COV-2 Infection Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2 Acute Kidney Injury in Patients Hospitalized with Kidney disease is associated with in-hospital death of patients with COVID-19 Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients Patient Selection and Timing of Continuous Renal Replacement Therapy Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases Cutaneous manifestations in COVID-19: a first perspective Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 COVID-19) infectioninduced chilblains: A case report with histopathologic findings. JAAD Case Rep Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease Anosmia and Ageusia: Common Findings in COVID-19 Patients Strict tropism for CD71(+)/CD234(+) human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi Are Gastrointestinal Symptoms Specific for COVID-19 Infection? A Prospective Case-Control Study from the United States Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19 Neutrophil extracellular traps and thrombosis in COVID-19. medRxiv Data sharing is not applicable to this article as no new data were created or analyzed in this study.